JAK2 and breast carcinoma: To find out whether IL-6 could be regulated by different combinations of its downstream pathways including Jak2/Stat3 in various cancer cells, we pharmacologically inhibited the four IL-6 downstream pathways in six drug resistant cancer cell lines derived from cervical cancer, breast cancer, and lung cancer cells.